Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima

Read more

Medivir to present at the Redeye Growth Day

Read more

Change in the number of shares and votes in Medivir AB (publ)

Read more

Partner with Medivir

Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.